secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001437749-24-020615
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial
--------------------------------------------------------------------------

- Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.
- BARDA separately commits ~$343M from Project NextGen for a CRO to execute the 10,000-participant Phase 2b study.
- Phase 2b double-blinded trial will compare GeoVax's GEO-CM04S1 against an FDA-approved mRNA COVID-19 vaccine.
- Study is part of HHS Project NextGen, a $5B initiative for next-generation COVID-19 vaccines and therapeutics.
- GeoVax's dual-antigen vaccine candidate aims to induce durable antibody and T-cell immunity against variants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774924020615/0001437749-24-020615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774924020615/govx20240618_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-020615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer